Table 3.
Baseline characteristics of the patients with children and adolescent NPC stratified by low vs. high pretreatment EBV DNA.
| Characteristics | EBV DNA | EBV DNA | P |
|---|---|---|---|
| ≤40,000 | >40,000 | ||
| (%, n = 113) | (%, n = 34) | ||
| Age, years | 0.915 | ||
| ≤17 | 61 (54.0) | 18 (52.9) | |
| >17 | 52 (46.0) | 16 (47.1) | |
| Gender | 0.109 | ||
| Male | 81 (71.7) | 29 (85.3) | |
| Female | 32 (28.3) | 5 (14.7) | |
| Pathologic type | 1.000# | ||
| WHO II | 3 (2.7) | 0 (0) | |
| WHO III | 110 (97.3) | 34 (100.0) | |
| Pretreatment BMI, kg/m2 | 1.000* | ||
| <23 | 98 (86.7) | 30 (88.2) | |
| ≥23 | 15 (13.3) | 4 (11.8) | |
| T stage | 0.603 | ||
| T1 | 3 (2.7) | 1 (2.9) | |
| T2 | 8 (7.1) | 2 (5.9) | |
| T3 | 45 (39.8) | 16 (47.1) | |
| T4 | 57 (50.4) | 15 (44.1) | |
| N stage | 0.564 | ||
| N0 | 3 (2.7) | 1 (2.9) | |
| N1 | 29 (25.7) | 9 (26.5) | |
| N2 | 62 (54.9) | 15 (44.1) | |
| N3 | 19 (16.8) | 9 (26.5) | |
| Overall stage | 0.748 | ||
| I | 1 (0.9) | 0 (0) | |
| II | 3 (2.7) | 2 (5.9) | |
| III | 44 (38.9) | 11 (32.4) | |
| IV | 65 (57.5) | 21 (61.8) | |
| Combination with chemotherapy | 0.092 | ||
| No | 2 (1.8) | 1 (2.9) | |
| NAC | 18 (15.9) | 2 (5.9) | |
| CCT | 28 (24.8) | 6 (17.6) | |
| NAC + CCT | 65 (57.5) | 25 (73.5) | |
| Total dose of cisplatin, mg/m2 (mean ± SD) | 275.8 ± 95.3 | 291.8 ± 105.3 | 0.403 |
#
Fisher exact test.
*
Correction for continuity.
BMI, body mass index; NAC, neoadjuvant chemotherapy; CCT, concurrent chemotherapy; SD, standard deviation.